Quinine 300mg Tablet Franchise in Ahmedabad

Antimalarial & Fever Therapy Supplier in Mumbai

Quinshell 300 Tablet Distributor in Delhi

Malaria Treatment Tablet Franchise Opportunity in Bangalore

Antimalarial Tablet Stockist in Hyderabad
Quinine 300mg Export & Manufacturing in Chandigarh

Home/Products /quinine-300mg-tablet

Quinshell 300 Tablet

Composition : Quinine (300mg) Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹1/-

Quinshell 300 Tablet contains Quinine 300mg, an antimalarial agent indicated for the treatment of malaria and symptomatic relief of fever associated with Plasmodium infections. It helps in reducing parasite load and controlling high fever effectively.

Quinine works by interfering with the parasite’s ability to metabolize hemoglobin, leading to the destruction of Plasmodium species in the bloodstream. Its proven efficacy ensures rapid symptom resolution and is widely used in both adult and pediatric malaria management.

For distributors and healthcare suppliers, Quinshell 300 Tablet is a high-demand antimalarial therapy product, commonly supplied to hospitals, clinics, endemic regions, and government malaria control programs. Seasonal malaria incidence drives consistent demand year-round.

Adding Quinshell 300 Tablet to your antimalarial therapy segment creates strong opportunities in pharmacies, hospitals, clinics, export markets, and third-party manufacturing. Its clinical reliability, prescriber trust, and essential role in malaria management make it a valuable addition to pharmaceutical distribution portfolios.


Read More

About the Product

Quinshell 300 Tablet contains Quinine 300mg, an antimalarial agent indicated for the treatment of malaria and symptomatic relief of fever associated with Plasmodium infections. It helps in reducing parasite load and controlling high fever effectively.

Quinine works by interfering with the parasite’s ability to metabolize hemoglobin, leading to the destruction of Plasmodium species in the bloodstream. Its proven efficacy ensures rapid symptom resolution and is widely used in both adult and pediatric malaria management.

For distributors and healthcare suppliers, Quinshell 300 Tablet is a high-demand antimalarial therapy product, commonly supplied to hospitals, clinics, endemic regions, and government malaria control programs. Seasonal malaria incidence drives consistent demand year-round.

Adding Quinshell 300 Tablet to your antimalarial therapy segment creates strong opportunities in pharmacies, hospitals, clinics, export markets, and third-party manufacturing. Its clinical reliability, prescriber trust, and essential role in malaria management make it a valuable addition to pharmaceutical distribution portfolios.


Common side effects may include nausea, vomiting, headache, dizziness, or mild gastrointestinal discomfort. Rare but serious side effects include cardiac arrhythmias, severe hypersensitivity reactions, cinchonism (tinnitus, visual disturbances), or blood disorders. Immediate medical attention should be sought if severe symptoms occur.

Quinshell 300 Tablet is indicated for the treatment of uncomplicated and severe malaria, particularly due to Plasmodium falciparum, as prescribed by a healthcare professional. It may also be used in combination therapy as recommended in local malaria treatment guidelines.

Quinshell 300 Tablet should be taken exactly as prescribed, and the full course must be completed to prevent resistance. Caution is advised in patients with heart conditions, liver or kidney disease, or a history of hypersensitivity to quinine. Alcohol and other medications affecting heart rhythm should be avoided during therapy.

Store Quinshell 300 Tablet in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children and do not use beyond the expiry date printed on the packaging.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation